Market News AIOpen the app

Oric Pharmaceuticals, Inc. shares new information about its drug trial and plans a bigger study for 2027.

TrialRead the original at SEC EDGAR
Good for ORIC

In the 26-patient study, enozertinib shrank tumors, including brain tumors. Six patients had grade 3 side effects that resolved after dose changes, and survival results remain incomplete, but the tumor activity supports ORIC's drug program.

ORIC · Oric Pharmaceuticals, Inc.

AI read · Good for ORIC

The AI's read

The tumor reductions across different mutations, including in the brain, give ORIC encouraging evidence that enozertinib may help patients. Six patients had grade 3 side effects, but all resolved after dose changes, and no one stopped treatment because of side effects. Important questions remain. The study included 26 patients, survival results are incomplete, and the larger study is only planned for 2027. The reported tumor activity still supports a positive reading for ORIC.

Get alerts for ORIC

Follow Oric Pharmaceuticals, Inc. (ORIC) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ORIC
Free on the App Store and Google Play, or on the web.